Attest is developing solutions for health care providers to quickly and safely perform accurate metabolite testing at point-of-care. Our NMR instrument can detect and quantify metabolites important to human health and performance without breaking the skin. We also obviate recurring costs of lances, disposable test strips, or sensors.
Health care practitioners are often called upon to perform assisted blood glucose measurement in diverse settings such as nursing homes, long-term care facilities, hospitals, group medical practices, health fairs (diabetes screening), and senior centers. Unfortunately existing blood glucose test technology designed for single-user self monitoring presents an infection risk in multi-user institutional settings. The United States Center for Disease Control (CDC) attributes 15 outbreaks of Hepatitis to infection control breaks in diabetes management and is concerned that the true incidence is likely higher. Non-invasive magnetic resonance technology has the potential to successfully mitigate this infection risk, with lower recurring costs, and improved test accuracy for better insulin dosing decisions.
Globally there are 425 million people living with diabetes and about one-half are undiagnosed. In the United States it is estimated that about 38% of people living with diabetes are undiagnosed, costing $32B annually. Given improved patient outcomes and lower costs associated with early detection and intervention there is a strong need for improved diabetes screening. A non-invasive test instrument that is easy to use and can be safely deployed at health fairs, senior centers, and group medical practices provides a lower cost screening methodology.
Over fifteen small molecule metabolites have been detected and quantitated non-invasively in vivo by magnetic resonance spectroscopy. Many of these metabolites have important diagnostic and therapeutic roles. For example elevated L-lactate concentration in plasma is a biomarker for septic shock. Creatinine is a biomarker for renal function and levels are often closely monitored during chemotherapy. β-Hydroxybutyrate (BHB) is an important biomarker for diabetic ketoacidosis and also for monitoring seizure control. We envision portable NMR spectroscopy enabling a wide range of PoC medical testing for advancing human health and performance.